EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Osang Healthcare Co.,Ltd (036220) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Osang Healthcare Co.,Ltd KRW 7,897, price KRW 6,380, upside +23.8%, quality 55 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · KR

OH Some data Sep 24, 2026

Osang Healthcare Co.,Ltd

036220 · KQ

UndervaluedThe stock appears undervalued with acceptable quality.

✓Fair value 7,897 KRW · Undervalued (+24%)
!Quality 55/100
!Weak Growth (revenue 3y −12.8 %/yr)
!Loss over the last twelve months · -3.7% net margin (TTM) · fiscal year 2025 2.4%
!Low debt · negative free cash flow
·3.13% dividend yield
!Mixed vs. peers (4/10)
!Narrow moat 19/100
!Evidence only medium, so the estimate is less certain
Watch Osang Healthcare Co.,Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

27,578 KRW 2,048 KRW Fair Value 7,897 KRW Jun 2015 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 2,048 KRW – 27,578 KRW · fair‑value band 5,528 KRW – 7,897 KRW · the 6,380 KRW price screens below the 7,897 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Osang Healthcare Co. in your weekly email

Every Wednesday you see whether Osang Healthcare Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Osang Healthcare Co.,Ltd researches, develops, and sells various diagnostic biosensors in South Korea and internationally. The company offers diagnostic biosensors for blood glucose, hemoglobin A1c, cholesterol, immuno diagnosis, molecular diagnosis, and others. It also exports its products to approximately 110 countries worldwide.

Show more

Osang Healthcare Co.,Ltd researches, develops, and sells various diagnostic biosensors in South Korea and internationally. The company offers diagnostic biosensors for blood glucose, hemoglobin A1c, cholesterol, immuno diagnosis, molecular diagnosis, and others. It also exports its products to approximately 110 countries worldwide. The company was formerly known as Infopia Co., Ltd. and changed its name to Osang Healthcare Co.,Ltd in April 2017. Osang Healthcare Co.,Ltd was founded in 1996 and is headquartered in Anyang-si, South Korea.

Stock analysis

Osang Healthcare Co.,Ltd (036220) currently trades at 6,380 KRW, while our model-based Fair Value estimate is 7,897 KRW, implying the stock looks roughly 19.2% undervalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of 13,490 KRW per share, and 5 of the 14 models we run sit above the 6,380 KRW price.

Bear case: the Multiples group reads lowest at 3,786 KRW, and 9 of the 14 models stay below the price. Evidence for this calculation is medium.

Scenario range: 5,528 KRW (bear) to 7,897 KRW (bull), the price of 6,380 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Osang Healthcare Co.,Ltd reported revenue of 129B KRW in FY2025 versus 132B KRW in FY2021, a compound −0.7%/yr. Reported net income was 3.1B KRW in FY2025, compounding +20.8%/yr from FY2021.

Key figures

Market cap 87.7B KRW (≈ $64.5M) · P/S ratio 0.69 · Dividend yield 3.1% · Net margin 2.4% · Return on equity −1.6% · Return on assets (EBIT) 10.6% · Operating margin −19.2% · Revenue (TTM) 119B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).

What moves the price

The share trades about 58% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at 24%, 036220 screens cheaper than that median.

Fair Value models

Bear 5,528 KRW Fair Value 7,897 KRW Bull 7,897 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Residual Income 12,371 KRW 11,035 KRW 6,956 KRW 73
EPV 361.48 KRW 479.19 KRW 574.74 KRW 71
ROIC Compounder 361.48 KRW 479.19 KRW 574.74 KRW 69
All 14 models by family
Earnings-Based
Graham-Dodd 1,515 KRW 10,562 KRW 14,822 KRW 60
Lynch FV 3,767 KRW 5,381 KRW 6,995 KRW 58
PEG = 1.0 3,767 KRW 5,381 KRW 6,995 KRW 55
EPV 361.48 KRW 479.19 KRW 574.74 KRW 71
Multiples
P/E Multiple 4,677 KRW 6,236 KRW 7,795 KRW 63
P/S Multiple 2,840 KRW 3,786 KRW 4,733 KRW 58
P/B Multiple 2,840 KRW 3,786 KRW 4,733 KRW 55
EV/EBIT 2,510 KRW 3,553 KRW 4,596 KRW 65
EV/EBITDA 9,335 KRW 12,653 KRW 15,971 KRW 67
EV/Revenue 962.49 KRW 1,640 KRW 2,318 KRW 52
Asset-Based
NCAV (Graham) 10,067 KRW 13,490 KRW 20,135 KRW 54
Economic Profit
Residual Income 12,371 KRW 11,035 KRW 6,956 KRW 73
ROIC Compounder 361.48 KRW 479.19 KRW 574.74 KRW 69
Growth Earnings
Growth-Adj P/E 5,528 KRW 7,897 KRW 10,266 KRW 65

Open the full fair value analysis →

Notify me when 036220 reaches fair value

Put 036220 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 55/100

Of which business quality 56 · Market factors (momentum, volatility) 26

Profitability 23
Margins and returns on capital today
Quality Growth 100
Are margins and returns improving?
Cashflow 32
Earnings quality: real cash, not paper profit
Fin. Strength 78
Balance sheet, leverage, solvency risk
Investment 39
Disciplined investing over empire-building
Low Volatility 59
Calm price path (market factor)
Momentum 17
Price trend over the last 3–12 months (market factor)
52W Momentum 5
Distance to the 52-week high (market factor)
Net Issuance 78
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 20/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+59.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.8%
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+17.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+14.3%
Dividend (yield on the price)3.1%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−5% → 2%

Watch 036220, get fair value alerts →

Compare Osang Healthcare Co.,Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks

Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 55 · Above median
Fair Value upside +24% · Top 25%
Profitability
Return on assets −1% · Below median
Net margin (TTM) −4% · Below median
Operating margin (TTM) −19% · Bottom 25%
Growth and dividend
Revenue growth −29% · Bottom 25%
Dividend yield (TTM) 3.1% · Above median
Balance sheet
Debt / equity 0.11× · Above median

Valuation Multiplesvs Medical Devices median · lower = cheaper

EV/EBITDA 4.1× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)65 · sector 10
FUTURE (revenue growth)0 · sector 31
PAST (return on equity)0 · sector 7
HEALTH (low debt)95 · sector 97
DIVIDEND (yield)63 · sector 40

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $101.07 $74.79 −26%
Stryker Corporation SYK $273.40 $300.74 +10%
Medtronic plc MDT $89.30 $65.57 −27%
Boston Scientific Corporation BSX $44.62 $49.08 +10%
Edwards Lifesciences Corporation EW $86.82 $82.04 −6%
Siemens Healthineers AG SHL €37.21 €35.22 −5%
DexCom, Inc DXCM $87.73 $96.50 +10%
GE HealthCare Technologies Inc GEHC $66.27 $69.62 +5%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥156.68 ¥172.35 +10%
Koninklijke Philips N.V PHIA €21.85 €15.32 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Osang Healthcare Co.,Ltd · Fair Value
7,897 KRW +19%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Osang Healthcare Co.,Ltd Fair Value". https://www.fairvalue-calculator.com/stock/036220

Frequently asked questions

Is Osang Healthcare Co.,Ltd (036220) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 7,897 KRW versus a price of 6,380 KRW, about +24% upside (undervalued).
What is the fair value of 036220?
Our model-based fair value for Osang Healthcare Co.,Ltd is 7,897 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 6,380 KRW.
What is the quality score of 036220?
Osang Healthcare Co.,Ltd has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Osang Healthcare Co.,Ltd (036220)?
Our model-based price target is the fair value of 7,897 KRW (as of Sep 24, 2026) from 14 valuation models. Cautious scenario 5,528 KRW, optimistic scenario 7,897 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Osang Healthcare Co.,Ltd stock forecast for 2026?
Our models put fair value at 7,897 KRW, about +24% upside versus a price of 6,380 KRW (undervalued). Cautious scenario 5,528 KRW, optimistic scenario 7,897 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Osang Healthcare Co.,Ltd (036220)?
Osang Healthcare Co.,Ltd reported trailing-twelve-month revenue of about 119B KRW (latest available figure, as of Sep 24, 2026).
Does Osang Healthcare Co.,Ltd pay a dividend?
Osang Healthcare Co.,Ltd currently shows a dividend yield of about 3.13% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Osang Healthcare Co.,Ltd (036220)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Osang Healthcare Co.,Ltd it is 7,897 KRW per share (as of Sep 24, 2026), against a price of 6,380 KRW. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Osang Healthcare Co.,Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 036220 trades below its calculated fair value: price 6,380 KRW, fair value 7,897 KRW, a gap of about +24% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 036220?
No. The price is what the market pays today (6,380 KRW); the fair value is what the company's own numbers justify (7,897 KRW). For Osang Healthcare Co.,Ltd the two are 1,517 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Osang Healthcare Co.,Ltd worth?
The market values Osang Healthcare Co.,Ltd at about 87.7B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 6,380 KRW; our models calculate a fair value of 7,897 KRW per share.
What do the bullish and bearish scenarios say about 036220?
Our models span a range for Osang Healthcare Co.,Ltd: cautious scenario 5,528 KRW, base 7,897 KRW, optimistic 7,897 KRW per share (as of Sep 24, 2026, price 6,380 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Osang Healthcare Co.,Ltd (036220)?
Balance-sheet figures for Osang Healthcare Co.,Ltd (as of Sep 24, 2026): return on equity −1.6%, debt of 0.11 per unit of equity. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is 036220 from its 52-week high?
Osang Healthcare Co.,Ltd trades at 6,380 KRW, about 58% below its 52-week high of 15,305 KRW and 18% above the low of 5,390 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 7,897 KRW is for.
Which stocks are comparable to Osang Healthcare Co.,Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Osang Healthcare Co.,Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 6,380 KRW, calculated fair value 7,897 KRW (+24%), Quality Score 55/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 036220 calculated?
We run Osang Healthcare Co.,Ltd through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 7,897 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Osang Healthcare Co.,Ltd currently trades 24 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Osang Healthcare Co.,Ltd (036220)?
The closing price on Sep 23, 2026 was 6,380 KRW. Our model-based fair value is 7,897 KRW, about +24% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Osang Healthcare Co.,Ltd right now?
Solid quality (55/100) at a price below fair value, the discount is the argument here, not the business quality. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Osang Healthcare Co.,Ltd

How large is the market capitalisation of Osang Healthcare Co.,Ltd (036220)?
The market capitalisation of Osang Healthcare Co.,Ltd is 87.7B KRW (≈ $64.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Osang Healthcare Co.,Ltd (036220)?
The price-to-sales ratio of Osang Healthcare Co.,Ltd is 0.69 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Osang Healthcare Co.,Ltd (036220)?
The dividend yield of Osang Healthcare Co.,Ltd is 3.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Osang Healthcare Co.,Ltd (036220)?
The net margin of Osang Healthcare Co.,Ltd is 2.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Osang Healthcare Co.,Ltd (036220)?
The return on equity (ROE) of Osang Healthcare Co.,Ltd is −1.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Osang Healthcare Co.,Ltd (036220)?
On an EBIT basis the return on assets of Osang Healthcare Co.,Ltd is 10.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Osang Healthcare Co.,Ltd (036220)?
The operating margin of Osang Healthcare Co.,Ltd is −19.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Osang Healthcare Co.,Ltd (036220)?
Revenue at Osang Healthcare Co.,Ltd is growing −28.8% versus a year earlier (3y avg −12.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Osang Healthcare Co.,Ltd (036220) generate?
The free cash flow of Osang Healthcare Co.,Ltd is −12.8B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Osang Healthcare Co.,Ltd (036220) carry?
The net debt of Osang Healthcare Co.,Ltd is 22.3B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Osang Healthcare Co.,Ltd in the live analysis

One click puts Osang Healthcare Co.,Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.